spacer
home > ebr > winter 2001 > the legal aspects of venture capital finance in biotechnology
PUBLICATIONS
European Biopharmaceutical Review

The Legal Aspects of Venture Capital Finance in Biotechnology

Emerging New Areas of Business

In recent years it has been the general belief that biotechnology will be one of those new areas of technologyaround which new companies and new businesses will emerge. Today, that prediction rings true. Hundreds of new biotechnology companies have been established in the US and in Europe over the past few years, many of which have proved successful.The biotech sector is well-established in the UK, Germany, France and the Netherlands, and is developing rapidly in Northern Europe as well. Finland, Sweden and Denmark are amongst the most highly biotech-oriented countries in Europe. Vital biotechnology clusters are emerging in the Finnish cities of Turku, Helsinki and Kuopio, where the biotech industry is constantly creating new jobs. In turn here is a need for special biotech-oriented experts and professionals in the areas of marketing and business administration, law, auditing and tax matters.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Hanna Paloheimo and Ben Rapinoja, Lawyers at Borenius & Kemppinen Ltd Hanna Paloheimo specialises in industrial property rights and legal matters related to the commercialisation of biotechnology and life sciences. In addition to her LLM degree, Hanna received an MSc degree in genetics from Helsinki University. She also studied at Edinburgh University, UK, where she spent a year participating in a graduate honours course in immunology from 1994 to 1995. Before joining Borenius & Kemppinen, Hanna worked as a patent attorney with a pharmaceutical firm and as a research assistant in a molecular biology research group at Helsinki University.
Ben Rapinoja's areas of expertise are intellectual property rights (IPR) - in particular patents, trademarks and contract law. His legal practise relates to the licensing and commercial exploitation of IPR, as well as litigation within patent, trademark and copyright law. Ben advises expanding companies in the biotechnology and pharmaceutical sectors in matters related to corporate law and contracts. He also advises companies with interests in the information technology sector. Before joining Borenius & Kemppinen, Ben worked at the Ministry of Trade and Industry, gaining experience in IPR law. He was also a Finnish Government representative working with various groups of the European Union Council and Commission, the European Patent Organisation and international organisations specialising in IPR (such as WIPO and WTO).

spacer
Hanna Paloheimo
spacer
spacer
spacer
Ben Rapinoja
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KITE’S CAR T-CELL THERAPY YESCARTA® (AXICABTAGENE CILOLEUCEL) FIRST IN EUROPE TO RECEIVE POSITIVE CHMP OPINION FOR USE IN SECOND-LINE DIFFUSE LARGE B-CELL LYMPHOMA AND HIGH-GRADE B-CELL LYMPHOMA

Stockley Park, UK – 16 September, 2022 – Kite, a Gilead Company, today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta® (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. If approved, axicabtagene ciloleucel will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment. Although 60% of newly diagnosed LBCL patients will respond to their initial treatment, 40% will relapse or will not respond and need 2nd line treatment.
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement